Galactosemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Galactosemia or Classic galactosemia
is an autosomal recessive disorder of carbohydrate metabolism due to a severe
deficiency of the enzyme galactose-1-phosphate uridyltransferase that catalyzes
the conversion of galactose-1-phosphate and uridine diphosphate glucose to
uridine diphosphate galactose and glucose-1-phosphate. Upon consuming lactose
in the neonatal period, the affected infants develop a potentially lethal
disease process with multiorgan involvement. Complications include feeding
problems, failure to thrive, hepatocellular damage, bleeding, and E coli sepsis
in untreated infants. If a lactose-restricted diet is provided during the first
ten days of life, the neonatal signs usually quickly resolve, and the
complications of liver failure, sepsis, and neonatal death are prevented;
however, despite adequate treatment from an early age, children with classic
galactosemia remain at increased risk for developmental delays, speech
problems, and abnormalities of motor function.
- The incidence of Classic galactosemia
ranges from 1 to 2 cases in 50,000 births globally.
Thelansis’s “Galactosemia Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Galactosemiatreatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Galactosemia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Galactosemia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment